Lv1
18 积分 2025-02-27 加入
Changes in serum potassium in people with type 2 diabetes taking sodium-glucose co-transporter-2 inhibitors
4个月前
已完结
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
4个月前
已完结
Balancing acute medical management of acute kidney injury and hyperkalaemia versus medicines optimisation for long-term Cardio-Renal-Metabolic (CaReMe) diseases: a narrative review
4个月前
已关闭
Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials
4个月前
已完结
Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists
4个月前
已完结
Sodium-glucose cotransporter-2 inhibitors and abnormal serum potassium: a real-world, pharmacovigilance study
4个月前
已完结
A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes
4个月前
已完结
Updated best practice statements regarding sodium-glucose cotransporter 2 inhibitors and serum potassium levels
4个月前
已完结
Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD
4个月前
已完结
皖公网安备34019202002308
